GVN SARS-CoV-2 Perspectives
Long COVID: The Impact of Post-Acute Sequelae of COVID-19 (PASC)
Long COVID: The Impact of Post-Acute Sequelae of COVID-19 (PASC) November 12, 2021 There is mounting evidence of the importance and seriousness of the long-term effects of COVID-19. Post-acute sequelae of SARS-CoV-2 (PASC, or “long COVID”) is characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms (1). Approximately…
Read MoreNew Antivirals: Could They Be Game Changers?
November 1, 2021 There have been recent reports of potentially effective oral antiviral drugs, including RNA replicase and viral protease inhibitors. If these prove safe and effective, this may overhaul the care of patients with COVID-19 by preventing severe COVID-19 in infected patients and, possibly in the future, prevent infection after contamination. It is likely…
Read MoreNew Antivirals: Could They Be Game Changers?
New Antivirals: Could They Be Game Changers? November 1, 2021 There have been recent reports of potentially effective oral antiviral drugs, including RNA replicase and viral protease inhibitors. If these prove safe and effective, this may overhaul the care of patients with COVID-19 by preventing severe COVID-19 in infected patients and, possibly in the future,…
Read MoreSARS-CoV-2, Children, and Multi-Inflammatory Syndrome
October 1, 2021 With the advent of the school year and children returning to in-person classes, there comes a concern over consequences with respect to the spread of the highly contagious Delta variant. It has been accepted that children are not as susceptible to viral infection and severe illness as adults. However, the current prevalence…
Read MoreCovid-19 Vaccines or Natural Immunity – Do Both Protect?
Covid-19 Vaccines or Natural Immunity – Do Both Protect? September 10, 2021 In the current circumstances of disturbingly high rates of infection by the Delta variant and the concerns over obtaining effective vaccine coverage, the degree of protection provided to SARS-CoV-2 infected convalescent people is of clear relevance for natural immunity. Pei et al. estimate…
Read MoreVaccines and Variants
Vaccines and Variants August 16, 2021 Extensive vaccination had resulted in reduced COVID-19 cases and mortality in certain places, such as the United States and Israel, thus giving a cautious optimism that the worst of the pandemic was over. However, this turned out not to be the case, due to unpredicted factors. One was the…
Read MoreSARS-CoV-2 Lambda Variant: The New Kid on the Block
SARS-CoV-2 Lambda Variant: The New Kid on the Block July 19, 2021 The COVID-19 pandemic has been marked by the ongoing emergence of new genetic variants. Although SARS-CoV-2 is an RNA virus, its genome is relative stable, thanks to a proofreading polymerase. However, in a situation with extensive viral transmission globally, the evolution of SARS-CoV-2…
Read MoreDoes COVID-19 Curb or Promote the Progression of Cancer?
Does COVID-19 Curb or Promote the Progression of Cancer? July 2, 2021 One of the many questions about the long-term implications of COVID-19 is whether there might be some positive or negative consequences on cancer. The inflammatory milieu elicited by infection with SARS-CoV-2 might elicit pro-cancer effects as well as COVID-related immune-deficiency or increase DNA…
Read MoreImpact of the Delta Variant on Transmission, Vaccine, and Treatment Efficacy
Impact of the Delta Variant on Transmission, Vaccine, and Treatment Efficacy June 21, 2021 One of the consequences of unchecked SARS-CoV-2 infections is the generation of mutations that have the potential to increase infectivity and transmissibility, confer a degree of resistance to vaccines, neutralizing antibodies, and monoclonal antibody therapy, and in some cases generate false…
Read More